UCL researchers have developed an ultrasound helmet that enables deep brain stimulation without surgery, offering hope for Parkinson's and other neurological disorders.
We spoke with Tony Cecchin, Vice President and General Manager of Global Supplies at Zebra Technologies and President of Temptime Corporation, and Chris Caulfield, Vice President of Temptime Operations about their work supporting front-line workers and easing the shipment of medical products through the supply chain.
Mutlu Özcan, Prof. Dr Dr h.c., PhD from the University of Zürich, highlights Reconstructive Dentistry through new biomaterials and technologies, including the associated changes and challenges.
EU leaders today (25 March) decided not to create an export ban for AstraZeneca vaccines made for the UK - but the feud between AstraZeneca and the bloc remains close to the surface of future discussions.
The University of Manchester found that tinnitus could be a COVID-19 symptom - some patients of the virus are reporting a loss in hearing and ringing of the ears.
The Dexamethasone steroid has been used across the globe to help treat COVID-19 in the ICU - leading to atleast one million survivors of hospitalisation from the virus.
In a study of over 32,000 people, a US trial found the AstraZeneca vaccine was 100% effective against deaths caused by COVID-19 - the vaccine did not show any connection to blood clots.
Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.
According to a new YouGov poll, 61% of people in France now believe that the AstraZeneca vaccine is unsafe, with Germany following closely at 55% - creating fears about the potential impact of vaccine hesitancy on the rollout.
In a significant breakthrough for life science, Israeli scientists have succeeded in growing mice embryos in artificial wombs - completely outside the body.
The NHS released new information explaining that there would be a vaccine shortage in the UK from 29 March, meaning under-50s will wait longer for their first jab as second doses are given to the most vulnerable cohorts.
Dr Eugene Durenard, CEO of Hyperbolic Holdings GmbH discusses promising emerging technologies in the field of early detection and prevention of major chronic diseases.
Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.
Everard Munting, President of EUROSPINE, explains why sharing knowledge about spinal treatments on a global scale is the most effective way to develop best practice and enable early interventions.
The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.
